Emcure

Emcure Pharma shares slip 5% amid large trades; check all details here

According to Bloomberg data, 2.4 per cent equity or 4.64 million shares changed hands through multiple block deals. Buyers and sellers of the transactions were not known

Emcure Q2 PAT up 25%, domestic and international biz drive 13% revenue rise

The company's revenue from operations rose to Rs 2,269.8 crore, a 13.4 per cent increase from Rs 2,001.9 crore in Q2FY25

Emcure Pharma Q2 results: PAT rises 25% to ₹251 crore on strong sales

Emcure Pharmaceuticals on Tuesday reported a 25 per cent increase in profit after tax to Rs 251 crore in the September quarter, aided by strong sales performance across domestic and export markets. The drug firm posted a profit after tax (PAT) of Rs 202 crore during the July-September quarter of the last fiscal. Revenue from operations rose to Rs 2,270 crore in the second quarter as against Rs 2,002 crore in the year-ago period, Emcure Pharmaceuticals said in a statement. "We continue to augment our portfolio in all our focus markets through in-licensing and in-house developments. Novo Nordisk partnership positions us well in the fast-growing obesity segment and gives us an early entry, enabling us to shape the market, Emcure Pharmaceuticals Chief Executive Officer and Managing Director Satish Mehta said. The company remains focused on delivering strong growth along with margin improvement in all key businesses, he added. Shares of the company were trading 3.90 per cent down at Rs

Novo Nordisk, Emcure Pharmaceuticals tie up to expand Wegovy's girth

2.4 mg injectable Poviztra to mark next phase of weight-loss rollout

Top stocks to buy today: Shrikant Chouhan picks Emcure Pharma, ICICI Bank

Shrikant Chouhan, Head of Equity Research at Kotak Securities, has recommended buying shares of Emcure Pharmaceuticals and ICICI Bank today

One shot every six months: India could change HIV prevention forever

A long-acting HIV jab promises near-perfect protection at just $40 a year, but 115 nations must wait for India's approval of generic production

Emcure Pharma shares gain as JM Financial initiates coverage; check target

JM Financial initiated coverage on Emcure Pharma with a 'Buy' rating and a target price of ₹1,740, citing its growth prospects

Emcure Pharma, Sanofi India shares edge higher; what's behind the move?

Emcure Pharma stock was quoting at ₹1,382.5, up 1.5 per cent from the previous day's close of ₹1,362.5 as the company announced a distribution and promotion partnership with Sanofi India

Emcure enters distribution agreement with Sanofi for diabetes drugs

Emcure to distribute and promote Sanofi's oral anti-diabetic brands Amaryl and Cetapin in India, expanding access amid rising prevalence of uncontrolled diabetes

Emcure Pharma shares dip after 2.4% stake change hands in block trades

Emcure Pharma shares fell after about 4.53 million shares, or a 2.4 per cent stake, changed hands via block trades on the NSE

Emcure Pharma hits 10% upper circuit; gains 20% in three days; here's why

Emcure Pharma hit 10 per cent upper circuit after the pharma company's Q4 net profit stood at ₹197.2 crore as against ₹121 crore, up 62 per cent

Emcure Q4 profit jumps 63%, domestic business drives 19.5% revenue rise

Emcure Pharma posted strong March quarter results with 63% rise in net profit and 19.5% growth in revenue, driven by robust domestic demand and global segment performance

Emcure Pharmaceuticals share gains on foraying into daily supplements space

The uptick in the Emcure Pharmaceuticals share price came after the company announced its entry into the daily supplements space with the expansion of its Arth range

This pharma stock listed in July has rallied 10% in trade; Check details

The stock was listed on July 10, 2024, and made a stellar debut on Indian bourses with the shares getting listed at Rs 1,325.05 on the BSE, a 31.45 per cent premium over its issue price

Emcure Pharma shares climb 6% after strong growth in Q2FY25 results

Shares of Emcure Pharma jumped 6 per cent at Rs 1523.80 a piece on the BSE after the company reported a strong second quarter earnings for the financial year 2024-25 (Q2FY25)

Mankind Pharma plans Rs 9,000 crore raise for Bharat Serums acquisition

The move will position Mankind as a leader in the gynaecology-fertility segment, with an anticipated market share of around 20%, surpassing Emcure

Emcure Pharma lists at 31% premium; should you buy, sell or hold the stock?

Emcure Pharmaceuticals listing today: According to analysts, Emcure Pharma is quoting at a reasonable valuation with a niche opportunity to invest in the gynaecology & HIV antivirals therapeutic areas

Emcure Pharma listing: Stock makes solid debut on NSE, BSE with 31% premium

Emcure Pharmaceuticals listing: Stock made a strong market debut as they got listed at Rs 1,325, a 31 per cent premium over the issue price of Rs 1,008 on the NSE and BSE today

Stocks to watch, July 10: Angel One, Emcure Pharma, Mankind Pharma, M&M

Stocks to watch on July 10: Emcure Pharmaceuticals' shares are scheduled to make their debut on the stock exchanges on Wednesday

Investors lap up shares of Emcure, Bansal Wire; bids cross Rs 1.25 trillion

The demand for both issuances reflects the positive sentiment among investors and could be a harbinger for more initial public offerings (IPOs) in the coming weeks, said industry players